Innate Pharma (IPHA) Net Income towards Common Stockholders (2018 - 2025)

Innate Pharma (IPHA) has 8 years of Net Income towards Common Stockholders data on file, last reported at $25.3 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 140.55% year-over-year to $25.3 million; the trailing twelve-month figure through Dec 2025 stood at -$87.9 million (up 42.32% YoY), and the FY2025 full-year result was $25.3 million, up 367.63% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at $25.3 million, up from -$24.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $25.3 million in Q4 2025 and bottomed at -$131.3 million in Q4 2021.
• The 5-year median for Net Income towards Common Stockholders is -$25.4 million (2024), against an average of -$33.0 million.
• The widest annual swing landed in 2023, when Net Income towards Common Stockholders soared 894.03%; it then plunged 4411.67% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$131.3 million in 2021, then surged by 57.92% to -$55.2 million in 2022, then declined by 15.82% to -$64.0 million in 2023, then rose by 2.63% to -$62.3 million in 2024, then jumped by 140.55% to $25.3 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at $25.3 million (Q4 2025), -$24.2 million (Q2 2025), and -$62.3 million (Q4 2024), per Business Quant data.

Peer Comparison